Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

CME

Cystic Fibrosis -- No Longer Just a Disease of Pediatric Medicine

Emerging research suggests target-specific therapies for managing cystic fibrosis.
CME credit is no longer available for this conference.

Course Authors

Arindam Singha, M.D., and Stephen E. Kirkby, M.D.

Dr. Singha is Fellow, Pulmonary & Critical Care Medicine, The Ohio State University Medical Center, and Dr. Kirkby is Associate Professor, Pulmonary & Critical Care Medicine, The Ohio State University Medical Center and Nationwide Children’s Hospital, Columbus, OH.

Within the past 12 months, Drs. Singha and Kirkby have nothing to disclose relevant to this activity.

Albert Einstein College of Medicine, CCME staff and interMDnet staff have nothing to disclose relevant to this activity.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Discuss the basic pathogenesis of cystic fibrosis, and recent trends in survival and outcome;

  • List the diagnostic criteria including CFTR mutation;

  • Describe the organ specific manifestation of disease;

  • Manage both acute exacerbation and chronic disease including pharmacologic and non pharmacologic therapies;

  • Evaluate and apply the new and emerging disease-modifying therapies for CF.

 

TERMS AND CONDITIONS

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity

Courses You Might Like

Asthma Management: A Multi-Faceted Approach

Asthma action plans are designed to be individualized and developed jointly with the patient, and may be based on symptoms or peak flow measurements.
Authors: Cathy G. Benninger, R.N., M.S., C.N.P., and Jennifer W. McCallister, M.D.
Estimated Time: 1 Hour
More

Idiopathic Pulmonary Fibrosis

Table 1. Clinical Strategies for the Improvement of Asthma Control.
Authors: Ganesh Raghu, M.D., and Samuel G. Rayner, M.D.
Estimated Time: 2 Hours
More

The Role of Matrix Metalloproteinases (MMPs) in COPD

Elaboration of matrix metalloproteinases (MMPs), zinc-dependent proteases, within the airways contributes to COPD.
Authors: Robert Foronjy, M.D., and Jeanine D'Armiento, M.D., Ph.D.
Estimated Time: 1 Hour
More

Acute Lung Injury and the Acute Respiratory Distress Syndrome

ALI complicates a variety of medical and surgical conditions, most commonly severe sepsis, pneumonia and massive trauma.
Authors: Chirag V. Shah, M.D., M.S., and Jason D. Christie, M.D., M.S.
Estimated Time: 1 Hour
More

The Diagnosis and Management of Venous Thromboembolism

This month, Victor F. Tapson, M.D., discusses

present in acute PE. The diagnostic utility of plasma measurements of circulating D-dimer (a specific derivative of cross-linked fibrin) has been extensively evaluated in patients with PE. A number of D-dimer assays are available, and the sensitivity and specificity of these assays vary. A positive D-dimer test means that
Authors: Victor F. Tapson, M.D.
Estimated Time: 1 Hour
More

Idiopathic Pulmonary Fibrosis

This month, Harold R. Collard, M.D., and Talmadge E. King, Jr., M.D., discuss

Case Report A 65-year-old man presents with shortness of breath and cough. Over the last six months he has had increasing breathlessness with exertion. He has a dry cough that is worse with exertion. He is a
Authors: Harold R. Collard, M.D., and Talmadge E. King, Jr., M.D.
Estimated Time: 1 Hour
More